6:00 PM
 | 
Oct 04, 2012
 |  BC Extra  |  Clinical News

Cempra's solithromycin meets gonorrhea endpoint

Cempra Inc. (NASDAQ:CEMP) said solithromycin met the primary endpoint in a Phase II to treat uncomplicated urogenital gonorrhea infection. All 22 evaluable patients achieved successful bacterial eradication at day seven after a...

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >